Australia - englanti - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 323.5 g (equivalent: iodine, qty 150 g) - injection, solution - excipient ingredients: trometamol; hydrochloric acid; water for injections; sodium calcium edetate - the medicinal product is for diagnostic use only intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography.,oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), hemiography, hysterosalpingography, and in adults, children and premature babies for studies of the gastrointestinal tract.,intrathecal: onmipaque is indicated for lumbar, thoracic, cervical and total columnar myelography and in computerised tomography of the cns in adults and children.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - ivermectin - solution for injection - 1.0 percent weight/volume - ivermectin

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - ivermectin - solution for injection - 1.0 percent weight/volume - ivermectin

Australia - englanti - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - lenacapavir sodium, quantity: 473.1 mg (equivalent: lenacapavir, qty 463.5 mg) - injection, solution - excipient ingredients: macrogol 300; water for injections - sunlenca, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - ivermectin - solution for injection - 1.0 percent weight/volume - ivermectin

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 750 mg - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride extended-release tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings and precautions ). - known hypersensitivity to metformin hydrochloride. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 750 mg - metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. metformin hydrochloride extended-release tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride and metformin hydrochloride extended-release tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings and precautions ). 2. known hypersensitivity to metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Yhdysvallat - englanti - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. metformin hydrochloride extended-release tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) [ see  warnings and precautions (5.1) ]. - hypersensitivity to metformin. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see data] . there are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [se

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - metformin hydrochloride - oral solution - 500 mg/5ml - biguanides; metformin

Malta - englanti - Medicines Authority

lamda laboratories sa 59, ioannou metaxa str, karellas,koropi, attiki, greece - metformin hydrochloride - oral solution - metformin hydrochloride 1000 mg/5ml - drugs used in diabetes